Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry

Lüthi, Guillaume; Blangy, Valeria; Eap, Chin B.; Ansermot, Nicolas

doi:10.1016/j.jpba.2012.12.023

Cited by 23 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When applying the optimized method, the estimated LoD and LoQ were lower than those reported for the original method [15]. The estimated LoQ is lower than the value reported by Luthi and colleagues (0.1 ng/mL) [19]. Similarly, the sensitivity of the optimized method appeared to be lower than the value obtained by Regina and Karash [20].…”

Section: Discussionmentioning

confidence: 55%

Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision

Elarabi

Hasan²,

Marsden

et al. 2020

Pharmacopsychiatry

View full text Add to dashboard Cite

Introduction Compliance with sublingual buprenorphine/naloxone (SL-BUP/NX) is associated with higher abstinence from illicit opioid use. Therapeutic drug monitoring (TDM) has been recommended for adherence monitoring of buprenorphine (BUP) maintenance treatment for opioid use disorder (OUD), but to date there have been no reported clinical applications. In this TDM feasibility study, we investigated BUP assay precision in 15 adults with OUD who had been stabilized on buprenorphine/naloxone. Methods Using solid phase extraction, BUP recovery was contrasted at 100 mMol and 1 Molar of acetic acid wash solution. Precision was determined by applying the condition generating highest recovery using 0.2 ng/mL and 10 ng/mL standards. Four blood samples were drawn to examine the BUP peak and trough plasma concentrations, and BUP elimination rate was estimated. BUP recovery was examined again in a random sample and contrasted with the concentration predicted applying first-order kinetics. Results Higher BUP recovery was achieved with 1 Molar wash (94.3%; p=0.05). Precision ranged from 15–20%. The estimated limit of detection (LoD) and limit of quantitation (LoQ) were 0.02 and 0.069 ng/mL, respectively. BUP peak and trough concentrations were successfully examined, and BUP trough concentrations were replicated confirming steady state. BUP concentrations were predicted at a variance of −7.20% to 1.54 %. Conclusions TDM for BUP maintenance treatment of OUD is feasible, and simple adjustment of the assay conditions enhances BUP recovery.

show abstract

Section: Discussionmentioning

confidence: 55%

Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision

Elarabi

Hasan²,

Marsden

et al. 2020

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…With the following 10‐fold dilution using the mobile phase, the consistency of the sample and mobile phase was ensured so that the solvent evaporation and reconstitution process could be circumvented. Such simplification made the whole pretreatment procedure shorter than in many other previous studies (de Souza, Domingues, & Queiroz, ; Lüthi et al, ; Zheng, Wang, Hu, & Feng, ).…”

Section: Resultsmentioning

confidence: 95%

“…Although the widely used liquid–liquid extraction and solid‐phase extraction methods are highly specific, the intricate operating process and relatively long work‐up time make them difficult to introduce into daily clinical usage. In comparison, protein precipitation, which could also provide sufficient decontaminating efficiency, is simple and has been used for the purification of many psychotropic drugs (Lüthi, Blangy, Eap, & Ansermot, ). In the present study, after optimization, a mixture of acetonitrile and methanol (50:50 v /v) was used as the precipitating initiator to achieve the highest precipitation efficiency.…”

Section: Resultsmentioning

confidence: 99%

Development of a UPLC‐MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients

Wang

2017

Biomedical Chromatography

View full text Add to dashboard Cite

A highly feasible and reliable ultra-high performance liquid chromatography tandem mass spectrometry method was presented for therapeutic drug monitoring of five anti-schizophrenic drugs (amisulpride, olanzapine, aripiprazole, paliperidone and ziprasidone) simultaneously. To meet the requirements of practical clinical usage (easy handling, high throughput and cost effectiveness), the pretreatment process was simplified (only including protein precipitation and mobile phase dilution steps) and the UPLC separation cycle was set within 6 min. The whole methodology was carefully validated according to the latest international guidelines showing the excellent selectivity, accuracy, precision, applicability and stability. After a 10 month clinical application, a retrospective analysis of 253 positive samples was carried out to investigate conformance with the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie therapeutic reference range for Chinese patients. The results suggested good consistency for olanzapine, aripiprazole, paliperidone and ziprasidone, while for amisulpride, the plasma concentration level (445.2 ± 231.5 ng/mL) was relatively higher than the recommended range (100-320 ng/mL). We supposed that such phenomenon indicated the necessity of reconstructing a Chinese-specific therapeutic reference range for amisulpride treatment, which would be helpful to improve medication efficiency and safety for Chinese patients.

show abstract

“…Methods for quantification of buprenorphine and one or more major metabolites in plasma and/or urine include immunoassay [22,23], gas chromatography with various detectors [24–28], HPLC with single quadrupole or tandem quadrupole mass spectrometry [13,29–35], and most recently UPLC methods with mass spectrometry [36–40]. Various methods of sample preparation have also been described, including protein precipitation [40], liquid/liquid extraction [39], and solid-phase extraction [37,41,42].…”

Section: Introductionmentioning

confidence: 99%

“…Various methods of sample preparation have also been described, including protein precipitation [40], liquid/liquid extraction [39], and solid-phase extraction [37,41,42]. The most sensitive of the above assays generally have a lower limit of quantification of approximately 0.1 ng/mL for buprenorphine and 0.25 ng/mL for norbuprenorphine, and the glucuronide metabolites are often not analyzed.…”

Section: Introductionmentioning

confidence: 99%

High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography–mass spectrometry

Regina

Kharasch

2013

Journal of Chromatography B

View full text Add to dashboard Cite

A new method using ultra-fast liquid chromatography and tandem mass spectrometry (UFLC–MS/MS) was developed for the simultaneous determination of buprenorphine and the metabolites norbuprenorphine, buprenorphine-3β-glucuronide, and norbuprenorphine-3β-glucuronide in plasma and urine. Sample handling, sample preparation and solid-phase extraction procedures were optimized for maximum analyte recovery. All four analytes of interest were quantified by positive ion electrospray ionization tandem mass spectrometry after solid-phase microextraction. The lower limits of quantification in plasma were 1 pg/mL for buprenorphine and buprenorphine glucuronide, and 10 pg/mL for norbuprenorphine and norbuprenorphine glucuronide. The lower limits of quantitation in urine were 10 pg/mL for buprenorphine, norbuprenorphine and their glucuronides. Overall extraction recoveries ranged from 68–100% in both matrices. Interassay precision and accuracy was within 10% for all four analytes in plasma and within 15% in urine. The method was applicable to pharmacokinetic studies of low-dose buprenorphine.

show abstract

Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry

Cited by 23 publications

References 24 publications

Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision

Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision

Development of a UPLC‐MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients

High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography–mass spectrometry

Contact Info

Product

Resources

About